• Aspire Biopharma entered into a letter of intent to acquire Dura Driver Control Systems for USD 30 million in cash, subject to due diligence.
• Dura Driver Control Systems reported FY2025 revenue above USD 200 million, with adjusted EBITDA above USD 22 million on an unaudited basis.
• Transaction would shift Aspire toward a diversified operating profile, adding an automotive tier-one supplier with 11 facilities across North America, Europe, and Asia.
• DCS brings an IP portfolio of more than 310 patents, supporting long-term supply relationships across major automotive OEM platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016979), on April 16, 2026, and is solely responsible for the information contained therein.